ReviewRheumatology advances in practice2021
Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.
Review in Rheumatology advances in practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- The rising global burden of gout attributable to kidney dysfunction: a 30-year trend analysis and projections to 2036.Clinical rheumatology · 2026Article
- Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease.Gout, urate, and crystal deposition disease · 2025Article
- Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review.Journal of nephrology · 2025Article
- Efficacy of dotinurad in patients with severe renal dysfunction.Clinical and experimental nephrology · 2024Article
- Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).European journal of medical research · 2023Article
- Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.Clinical kidney journal · 2023Review
- Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.Frontiers in endocrinology · 2022Review
- Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.Nature reviews. Rheumatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim was to evaluate the efficacy, defined as achieving target serum urate <6.0 mg/dl, and safety of urate-lowering therapies (ULTs) for people with gout and chronic kidney disease (CKD) stages 3-5.
methodsPubMed, The Cochrane Library and EMBASE were searched from 1 January 1959 to 31 January 2018 for studies that enrolled people with gout, who had an estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) of <60 ml/min and exposure to allopurinol, febuxostat, probenecid, benzbromarone, lesinurad or pegloticase. All study designs other than case reports were included, except for people on dialysis, for whom we did include case reports.
resultsThere were 36 reports with an analysis of efficacy and/or safety based upon renal function: allopurinol (
conclusionThere is a lack of evidence regarding the efficacy and/or safety of currently used ULTs according to different levels of renal function. Future studies should include patients with CKD and should report study outcomes stratified by renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.